Compare LDI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LDI | MNPR |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 607.4M | 587.4M |
| IPO Year | 2021 | 2019 |
| Metric | LDI | MNPR |
|---|---|---|
| Price | $1.01 | $109.87 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $3.00 | ★ $107.00 |
| AVG Volume (30 Days) | ★ 1.9M | 210.1K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.58 | N/A |
| Revenue Next Year | $13.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $29.18 |
| 52 Week High | $5.05 | $116.64 |
| Indicator | LDI | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 36.43 | 62.67 |
| Support Level | N/A | $52.92 |
| Resistance Level | $1.32 | $112.57 |
| Average True Range (ATR) | 0.07 | 8.75 |
| MACD | -0.01 | -0.80 |
| Stochastic Oscillator | 29.45 | 67.27 |
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.